Replace Iron and Maintain Hemoglobin without Increasing Iron Stores
Triferic is a revolutionary iron therapy that replaces iron and maintains hemoglobin without increasing iron stores, and Triferic is the only FDA approved product indicated to replace iron and maintain hemoglobin concentration in adult HDD-CKD hemodialysis patients – there is no other iron product like Triferic.
Over the course of the 4-hour hemodialysis treatment, blood loss occurs. This blood loss equates to a 5-7 milligram of iron lost every dialysis treatment. So, dialysis patients are losing about 1 gram of iron over the course of every year they are on dialysis, and this iron loss is a primary driver of their anemia. There has been nothing available to treat this constant loss of iron… until now with Triferic.
Triferic slowly infuses 5-7 milligrams of iron during every dialysis treatment, simply replacing the iron that was lost during dialysis; similar to how we replace magnesium, potassium and calcium during every dialysis treatment. Iron delivery via dialysate is innovative, and convenient, but what makes Triferic really special is that once it enters the blood it binds immediately to transferrin (the carrier of iron in the body) and is transported to the bone marrow for hemoglobin incorporation; there is no non-transferrin bound iron available and no free iron is stored in the body.
This is in stark contrast to current IV iron therapy, where a large dose of iron is injected quickly into the blood of the patient and then becomes trapped in the patients liver (due to related inflammation) instead of binding to transferrin. The result has been a steady, significant increase in patient ferritin (stored iron and inflammation) levels. IV iron is also linked to toxicity, infections and can cause severe hypersensitivity reactions. IV iron has been around for over 25 years and has been used in dialysis patients only because there has been nothing better to use… until now with Triferic. Triferic is true iron maintenance therapy.
1 Rockwell Medical, Inc. Data on File. Independent Market Research Study Conducted in August 2015 with 103 U.S. Based Nephrologists – Based upon efficacy, safety, most appealing aspect, contrast to IV iron and choice between Triferic and IV iron.
2 In Clinical Trials vs. Placebo. Triferic® Package Insert. Rockwell Medical, Wixom, MI, October 2017